Gene-silencing to curb LDL-C ‘could dramatically cut CVD risk’
Researchers have attempted to simulate a 50-year randomised controlled trial.
AusDoc brings you the latest news from the European Society of Cardiology Congress 2021.
Having an annual ‘vaccination’ from the age of 30 to reduce LDL-cholesterol (LDL-C) levels could have a dramatic effect on the risk of major cardiovascular events, UK researchers say.